Abbott's Ultreon 3.0 AI System Receives FDA and CE Approval for Coronary Imaging
Abbott recently received important regulatory approvals for its state-of-the-art Ultreon™ 3.0, an advanced imaging system designed for coronary interventions. This next-generation platform has been cleared by the U.S. Food and Drug Administration (FDA) and also received the CE Mark in Europe, marking a significant achievement in medical imaging technology. The Ultreon 3.0 integrates optical coherence tomography (OCT) and artificial intelligence (AI), enabling physicians to visualize coronary plaques in high detail while receiving automated insights to guide their clinical decisions.
Dr. Evan Shlofmitz, an interventional cardiologist, highlighted the importance of this technology, stating that it not only enhances existing capabilities but significantly advances how cardiologists treat heart disease. The integration of imaging and AI allows for real-time guidance during minimally invasive procedures known as percutaneous coronary intervention (PCI), where blockages in the coronary arteries are addressed. The system captures detailed images of the arterial structure, helping healthcare providers assess the type of blockage and determine the optimal stent size and position.
The Ultreon 3.0 stands out due to its one-second OCT pullback feature, which uses rapid infrared light to provide comprehensive cross-sectional views of the coronary arteries. Compared to traditional intravascular ultrasound (IVUS), this imaging method offers superior resolution at lower or no contrast, beneficial for patients with compromised kidney function—a demographic that constitutes around 25% of individuals with coronary artery disease.
Additionally, the Ultreon 3.0 provides clinicians with a clearer comprehension of the blockages, facilitating precise stent placement, and ensuring that the post-procedure assessments confirm improved blood flow within the arteries. This systematic approach bolsters the workflow for physicians, allowing for quicker and more informed clinical choices that can dramatically impact patient outcomes.
David M. Leistner, another interventional cardiologist, emphasized the time-sensitive nature of treating such conditions, noting that every moment counts when managing patients with coronary artery blockages. With the speed and insight offered by Ultreon 3.0, doctors can create actionable plans swiftly, potentially saving lives.
Abbott's chief medical officer for vascular operations, Dr. Ethan Korngold, remarked on how Ultreon 3.0 redefines the role of imaging in interventional cardiology, making it an intuitive and powerful tool for precision-guided interventions. As the number of PCI procedures continues to grow, with over 600,000 performed annually in the United States alone, Abbott's Ultreon 3.0 is positioned to propel advancements in coronary care. It builds upon the successes of its predecessor, Ultreon 2.0, by introducing enhanced AI capabilities tailored for complex coronary cases.
For healthcare professionals involved in interventional cardiology, Ultreon 3.0 represents a leap forward, enabling increased efficiency and accuracy in one of the most critical areas of cardiovascular care. In light of these developments, Abbott continues to assert its leadership in AI-powered imaging, signifying its commitment to deliver smarter, more personalized care solutions. For those looking for further insights on this breakthrough technology, detailed safety information is available through Abbott's official channels.
Dr. Evan Shlofmitz, an interventional cardiologist, highlighted the importance of this technology, stating that it not only enhances existing capabilities but significantly advances how cardiologists treat heart disease. The integration of imaging and AI allows for real-time guidance during minimally invasive procedures known as percutaneous coronary intervention (PCI), where blockages in the coronary arteries are addressed. The system captures detailed images of the arterial structure, helping healthcare providers assess the type of blockage and determine the optimal stent size and position.
The Ultreon 3.0 stands out due to its one-second OCT pullback feature, which uses rapid infrared light to provide comprehensive cross-sectional views of the coronary arteries. Compared to traditional intravascular ultrasound (IVUS), this imaging method offers superior resolution at lower or no contrast, beneficial for patients with compromised kidney function—a demographic that constitutes around 25% of individuals with coronary artery disease.
Additionally, the Ultreon 3.0 provides clinicians with a clearer comprehension of the blockages, facilitating precise stent placement, and ensuring that the post-procedure assessments confirm improved blood flow within the arteries. This systematic approach bolsters the workflow for physicians, allowing for quicker and more informed clinical choices that can dramatically impact patient outcomes.
David M. Leistner, another interventional cardiologist, emphasized the time-sensitive nature of treating such conditions, noting that every moment counts when managing patients with coronary artery blockages. With the speed and insight offered by Ultreon 3.0, doctors can create actionable plans swiftly, potentially saving lives.
Abbott's chief medical officer for vascular operations, Dr. Ethan Korngold, remarked on how Ultreon 3.0 redefines the role of imaging in interventional cardiology, making it an intuitive and powerful tool for precision-guided interventions. As the number of PCI procedures continues to grow, with over 600,000 performed annually in the United States alone, Abbott's Ultreon 3.0 is positioned to propel advancements in coronary care. It builds upon the successes of its predecessor, Ultreon 2.0, by introducing enhanced AI capabilities tailored for complex coronary cases.
For healthcare professionals involved in interventional cardiology, Ultreon 3.0 represents a leap forward, enabling increased efficiency and accuracy in one of the most critical areas of cardiovascular care. In light of these developments, Abbott continues to assert its leadership in AI-powered imaging, signifying its commitment to deliver smarter, more personalized care solutions. For those looking for further insights on this breakthrough technology, detailed safety information is available through Abbott's official channels.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.